Think Surgical announces first TMINI robotic procedures using LinkSymphoKnee
March 9, 2025
Think Surgical today announced the first successful use of Waldemar Link’s LinkSymphoKnee using the TMINI Miniature Robotic System.
Think Surgical today announced the first successful use of Waldemar Link’s LinkSymphoKnee using the TMINI Miniature Robotic System.
Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine investigators. The new approach, which requires further development and testing, could someday enable the much wider use of islet transplants to cure diabetes.
COPENHAGEN, Denmark, Feb. 19, 2025 /PRNewswire/ — CathVision, a medical technology company developing advanced electrophysiology solutions, is proud to announce that it has received CE Mark for its breakthrough product, ECGenius System. This regulatory milestone allows CathVision to market and distribute ECGenius System across the European Economic Area (EEA), bringing state-of-the-art electrophysiology solutions to healthcare providers and patients.
Boston Scientific (NYSE: BSX)+
announced today that it received CE mark for its navigation-enabled Farawave Nav ablation catheter and Faraview software.
TAMPERE, Finland, Feb. 14, 2025 /PRNewswire/ — Bioretec Ltd., a pioneer in absorbable orthopedic implants, has achieved a pivotal milestone with the successful completion of its CE mark approval process for the RemeOs™ Trauma Screw product portfolio
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 diabetes.
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted treatments known as CDK4/6 inhibitors. A new study led by Agnieszka Witkiewicz, MD, and Erik Knudsen, Ph.D., of Roswell Park Comprehensive Cancer Center and colleagues highlights the therapeutic impact of CDK2 inhibitors and is published in the journal Nature Communications.
The U.S. Senate voted 52–48 today to confirm Robert F. Kennedy Jr. as the new secretary of the U.S. Department of Health and Human Services.
BOSTON, Feb. 11, 2025 /PRNewswire/ — InnoVoyce, a leading medical technology company, proudly announces its ISO 13485:2016 certification, underscoring its dedication to excellence in the design, manufacturing, installation, and servicing of lasers and fiber devices. Alongside this milestone, the company is thrilled to share that its FDA-cleared VYLO™ 455nm Blue Light Laser System is now available nationwide, offering healthcare professionals an advanced tool for treating laryngeal disorders and a wide range of surgical applications.